New treatment options for panic disorder: clinical trials from 2000 to 2010
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the longer these patients remain without treatment, the worse the prognosis will be. AREAS COVERED: The authors carried out a systematic review of the literature regarding the pharmacological treatment of PD in the last 10 years. Only open studies, placebo-controlled studies or comparative clinical trials were selected. EXPERT OPINION: Compounds with reported effectiveness in the treatment of PD included tricyclic antidepressants, benzodiazepines, serotonin selective reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs) and other drugs. SSRIs and SNRIs are the first-line compounds in the treatment of PD. These drugs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications. The serotonergic, noradrenergic and GABAergic pathways play a major role in the fear network and in the physiopathology of PD. A better understanding of the role of these neurotransmitter systems in PD will allow the development of more effective drugs for this psychiatric condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A meta-analysis of treatment outcome for panic disorder
Gould, R. A., Ott, M. W., & Pollack, M. H. (1995) · Clinical Psychology Review · doi:10.1016/0272-7358(95)00048-8 · Cited by 520 · cited 4×
“Clinical trials conducted before the year 2000 indicated that the antidepressants imipramine, clomipramine, phenelzine, citalopram, fluvoxamine, fluoxetine, paroxetine, sertraline and venlafaxine were all effective antipanic medications and the efficacy was similar among them [16,20,22].”
InfluentialRoy-Byrne, P. P., Stang, P., Wittchen, H.-U., Ustun, B., Walters, E. E., & Kessler, R. C. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.229 · Cited by 446
Panic disorder and control of breathing
Nardi, A. E., Freire, R. C., & Zin, W. A. (2009) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2008.07.011 · Cited by 151
Self-citationHirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., & Grunhaus, L. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200010000-00011 · Cited by 89 · cited 3×
“In the first study, either a combination of fluoxetine and pindolol or fluoxetine and placebo was administered to treatmentresistant PD patients for 4 weeks [57].”
Sertraline treatment of panic disorder: results of a long-term study
Rapaport, M. H., Wolkow, R., Rubin, A., Hackett, E., Pollack, M., & Ota, K. Y. (2001) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2001.00263.x · Cited by 79
Perna, G., Bertani, A., Caldirola, D., Smeraldi, E., & Bellodi, L. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-14283 · Cited by 64 · cited 2×
“Citalopram 20 -- 50 Paroxetine 20 -- 50 Perna 2001 [53] Sertraline 50 -- 150 Paroxetine 40 -- 60 Bandelow 2004 [48] Sertraline 50 -- 200 Imipramine 1.”
Aripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder
Hoge, E. A., Worthington, J. J., Kaufman, R. E., Delong, H. R., Pollack, M. H., & Simon, N. M. (2008) · CNS Spectrums · doi:10.1017/s109285290001676x · Cited by 58 · cited 4×
“5 -- 2 Pollack 2003 [58] Medication* -Aripiprazole 5 -- 30 Hoge 2008 [59] SSRIz -Olanzapine 5 Sepede 2006 [60] Fluoxetine 20 Pindolol 7.”
InfluentialBertani, A., Perna, G., Migliarese, G., Di Pasquale, D., Cucchi, M., Caldirola, D., & Bellodi, L. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832593 · Cited by 49 · cited 3×
“The reduction of PASS and other severity scale scores was significantly greater in the paroxetine group than in the reboxetine one [56].”
Dannon, P. N., Iancu, I., & Grunhaus, L. (2002) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.421 · Cited by 41 · cited 4×
“1 Open studies In open studies, citalopram [29], venlafaxine [30], mirtazapine [31-33], reboxetine [34], nefazodone [35], sertraline [36], duloxetine [37] and the combined treatment with clonazepan and milnacipran [38] have proven effective and well tolerated in the treatment of PD.”
Influential
Cited by
Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
Treatment–resistant panic disorder: a systematic review
Freire, R. C., Zugliani, M. M., Garcia, R. F., & Nardi, A. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1109628 · Cited by 47
Self-citationPanic disorder respiratory subtype: psychopathology and challenge tests – an update
Okuro, R. T., Freire, R. C., Zin, W. A., Quagliato, L. A., & Nardi, A. E. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0717 · Cited by 23
Self-citationEmerging drugs for panic disorder
Perna, G., Guerriero, G., & Caldirola, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.628313 · Cited by 23
Metadata
- Authors
- Freire, R. C., Hallak, J. E., Crippa, J. A., & Nardi, A. E.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-02-23
- Volume
- 12
- Issue
- 9
- Pages
- 1419-1428
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2162225122
- Cited by
- 37
- References
- 9
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New treatment options for panic disorder: clinical trials from 2000 to 2010. https://app.cochat.ai/papers/10.1517/14656566.2011.562200
- The paper
- Freire, R. C., Hallak, J. E., Crippa, J. A., & Nardi, A. E. (2011). New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2011.562200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.